The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.
Saved in:
| Title: | The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. |
|---|---|
| Authors: | Reader CS; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Vallath S; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Steele CW; Cancer Research UK Beatson Institute, Glasgow, UK., Haider S; Institute of Cancer Research, London, UK., Brentnall A; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK., Desai A; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Moore KM; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Jamieson NB; Academic Unit of Surgery, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK., Chang D; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Bailey P; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Scarpa A; ARC-NET Research Centre for Applied Research on Cancer, University of Verona, Verona, Italy., Lawlor R; ARC-NET Research Centre for Applied Research on Cancer, University of Verona, Verona, Italy., Chelala C; Centre for Molecular Oncology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Keyse SM; Division of Cancer Research, University of Dundee, James Arrott Drive, Ninewells Hospital and Medical School, Dundee, UK., Biankin A; Centre for Molecular Oncology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Morton JP; Cancer Research UK Beatson Institute, Glasgow, UK., Evans TJ; Cancer Research UK Beatson Institute, Glasgow, UK.; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Barry ST; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Sansom OJ; Cancer Research UK Beatson Institute, Glasgow, UK., Kocher HM; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK., Marshall JF; Centre for Tumour Biology, Barts Cancer Institute, CRUK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, UK. |
| Source: | The Journal of pathology [J Pathol] 2019 Nov; Vol. 249 (3), pp. 332-342. Date of Electronic Publication: 2019 Jul 30. |
| Publication Type: | Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-9896 |
|---|---|
| DOI: | 10.1002/path.5320 |
